MGMT and colorectal carcinoma: The results of the 2022 MAYA clinical trial indicated that temozolomide (TMZ) may enhance the sensitivity of patients with methylguanine methyltransferase (MGMT)-silenced, MSS CRC to the combination of ipilimumab and nivolumab [77].